【product description】
Nintedanib is a triple angiokinase inhibitor that can simultaneously target and inhibit three major receptors that lead to angiogenesis and tumor growth, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR).
【Indications】
For the treatment of idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease, and chronic fibrotic interstitial lung disease.
【Dosage】
Recommended dosage: 150mg twice a day.
Recommended dose for patients with mild hepatic insufficiency (Child Pugh A): 100 mg twice a day, with an interval of about 12 hours, with food.
Before starting treatment, liver function tests and a pregnancy test should be done.
商品評價
目前沒有評價。